TSS
ALLO icon

Two Sigma Securities’s Allogene Therapeutics ALLO Stock Holding History

Two Sigma Securities’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,230
Closed -$16.8K – 1628
2025
Q4 		$16.8K Sell
12,230
-10,895
-47% -$14.4K ﹤0.01% 1203
2025
Q3 		$28.7K Buy
23,125
+86
+0.4% +$103 ﹤0.01% 1075
2025
Q2 		$26K Buy
+23,039
New +$30.6K ﹤0.01% 1170

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Securities's ALLO Position: Q1 2026 in Review

Two Sigma Securities sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 12,230 shares — an estimated $16.8K sold.

Two Sigma Securities first reported a position in ALLO in Q2 2025 and held it in 3 quarters. The position peaked at $28.7K in Q3 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Two Sigma Securities reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 12,230 Allogene Therapeutics shares in Q1 2026, an estimated $16.8K.
  • Two Sigma Securities first reported a position in Allogene Therapeutics in Q2 2025 and held it in 3 quarters.
  • Two Sigma Securities's Allogene Therapeutics position peaked at $28.7K in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.